Skip to main content
Download PDF

Increased gene expression and copy number of mutated blaKPC lead to high-level ceftazidime/avibactam resistance in Klebsiella pneumoniae

BMC Microbiology volume 21, Article number: 230 (2021) Cite this article

Abstract

Background

Resistance to ceftazidime-avibactam was reported, and it is important to investigate the mechanisms of ceftazidime/avibactam resistance in K. pneumoniae with mutations in blaKPC.

Results

We report the mutated blaKPC is not the only mechanism related to CZA resistance, and investigate the role of outer porin defects, efflux pump, and relative gene expression and copy number of blaKPC and ompk35/36. Four ceftazidime/avibactam-sensitive isolates detected wild type blaKPC-2, while 4 ceftazidime/avibactam-resistant isolates detected mutated blaKPC (blaKPC-51, blaKPC-52, and blaKPC-33). Compared with other ceftazidime/avibactam-resistant isolates with the minimal inhibitory concentration of ceftazidime/avibactam ranging 128–256 mg/L, the relative gene expression and copy number of blaKPC was increased in the isolate which carried blaKPC-51 and also showed the highest minimal inhibitory concentration of ceftazidime/avibactam at 2048 mg/L. The truncated Ompk35 contributes rare to ceftazidime/avibactam resistance in our isolates. No significant difference in minimal inhibitory concentration of ceftazidime/avibactam was observed after the addition of PABN.

Conclusions

Increased gene expression and copy number of mutated blaKPC can cause high-level ceftazidime/avibactam resistance.

Background

Carbapenem-resistant Enterobacerales (CRE), especially carbapenem-resistant Klebsiella pneumonia (CRKP) have emerged as a major public health concern worldwide. In China, the production of K. pneumoniae carbapenemases (KPCs) is the predominant mechanism of carbapenem resistance and is frequently linked to a highly successful K. pneumoniae sequence type 11(ST11) clone [1]. The existing antibiotics treating infections caused by KPC-producing K. pneumoniae (KPC-Kp) have limited efficacy, and novel antibiotics are urgently needed.

Avibactam is a non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes. Ceftazidime/avibactam (CZA) has been considered a promising β-lactam-β-lactamase inhibitor combination with activity against serine β-lactamases, including KPCs [2]. However, CZA resistance has been reported in patients after short periods of CZA exposure [3,4,5,6,7,8,9,10,11,12,13,14,15,16,17], and also in patients with no history of CZA therapy [18,19,20,21,22,23]. Mechanisms of CZA resistance have reported in several studies, including specific mutations in the blaKPC gene [4], specific mutations in the blaCTX-M gene [17], porin deficiency combined with high ceftazidime hydrolysis [19, 20], or porin inactivation with increased expression of the blaKPC gene [21, 22]. The mechanism most often associated with the emergence of CZA resistance after treatment has been observed to be mutations in the blaKPC gene encoding for KPC enzymes [4,5,6,7,8,9,10,11,12]. And the most common amino acid substitution of KPC was D179Y in KPC-2 (KPC-33) [6] and KPC-3 (KPC-31) [4].

CZA has been approved by the China State Drug Administration on May 21, 2019, for the treatment of complex intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), and for the treatment of gram-negative bacterial infections in adults with limited therapeutic options: K. pneumoniae, E. cloacae, E. coli, Proteus mirabilis, and Pseudomonas aeruginosa. Before the wide use of CZA, CZA-resistant isolates carrying wild type KPC-2 have been reported in China [19, 23]. Besides, we reported our experience in treating ten lung transplant recipients (9 with KPC-Kp infections, and 1 with Pseudomonas aeruginosa infection) with CZA at the China-Japan friendship hospital [24]. CZA resistant KPs with mutated blaKPC were recovered from 4 patients after CZA treatment [25]. Plasmid transfer and blaKPC cloning showed the mutated blaKPC in these isolates were associated with CZA resistance. We observed that the minimal inhibitory concentration (MIC) for CZA of KPC-51-producing K. pneumoniae clinical isolate was the highest (2048 mg/L) in our study, while the CZA MIC for the KPC-51-harbouring E. coli DH5a transformant was only 8 mg/L. We believed that the mutated blaKPC was only partly contributing to the resistance of CZA in this isolate, and other resistance mechanisms should be further investigated. Besides, though increased gene expression and copy number of blaKPC and/or porins defects were reported associated with CZA resistance, this finding was often reported in isolates with wild type blaKPC, and rarely reported in isolates with mutated blaKPC. The role of blaKPC expression and porins in CZA resistant isolates with mutated blaKPC is not clear, especially in isolates with different resistant levels.

Results

Bacterial isolates

After 13–22 days of CZA treatment in lung transplant patients, CZA resistance was found in 4 isolates. These 4 CZA resistant isolates (1B, 3B, 7B, 8B) and 4 baseline isolates (1A, 3A, 7A, 8A) recovered before CZA treatment from the same patients were analyzed in the present study. All 8 isolates produced KPC, and other beta-lactamases were detected (Table 1). Four baseline isolates carrying wild type blaKPC-2 were susceptible to CZA, while the blaKPC of corresponding CZA-resistant isolates were mutated after CZA treatment. KPC-33(D179Y), KPC-51(D179N, Y241H, H274N), and KPC-52(D179Y, valine insertion after 262 position) were observed in 8B, 1B, and 7B, respectively. Among the 1228 reads covering KPC in the next-generation sequencing data of isolate 3B, 349 reads (28.4%) belonged to KPC-2, and 879 reads (71.6%) belonged to KPC-33. The transformed E.coli isolates carrying mutated blaKPC manifested increased CZA MICs compared with the WT blaKPC-2 transformant. The CZA MIC of 3B, 7B, and 8B were 256, 256, and 128 mg/L, and the CZA MIC in corresponding transformed E. coli isolates harboring the same blaKPC variants were 2, 32, and 2 mg/L, respectively [25]. It is worth noting that the CZA MIC of KPC-51-producing K. pneumoniae clinical isolate 1B was the highest (2048 mg/L) in our study, while the CZA MIC for the KPC-51-harbouring E. coli DH5a transformant was only 8 mg/L. Other beta-lactamases detected in isolates from the same patient were identical.

Table 1 Characteristics of isolates recoverd from the same patients before (A) and after (B) ceftazidime/avibactam exposure
Full size table

Outer membrane porin gene sequence analysis

Compared with the sequences of wild type ompk35 (NCBI reference sequence WP_135730820.1) and ompk36 (GenBank accession number AEW62399.1) genes from the reference strain K. pneumoniae ATCC13883, the ompk35 sequence of all 8 isolates had a deletion after 85 bp, which caused a premature stop codon after amino acid position 62. And the Ompk36 in all 8 isolates had a glycine and aspartic acid duplication at amino acid 136 (136–137 GD insertion) (Table 1). Different sequences of Ompk35 and Ompk36 were not found between the baseline isolates (A) and CZA resistant isolates (B) recovered from the same patient.

Functional restoration of OmpK35 and Ompk36

The blunt vectors harboring functional wild-type Ompk35 or Ompk36 were transferred into selected isolates with different KPC variants by electroporation. The profiles of outer membrane proteins in all clinical isolates and transformants were analyzed by SDS-PAGE (Fig. 1). The truncated Ompk35 in clinical isolates were not shown, while the restoration of lost Ompk35 in corresponding transformants was confirmed in the profiles. The mutated Ompk36 did not influence the profiles of outer membrane proteins in clinical isolates. As a control, the empty blunt vector was also transferred into clinical isolates. The existence of wild type Ompk36 and empty blunt vector in corresponding transformants can not be reflected by SDS-PAGE, but it was confirmed using PCR and sequencing. Compared with clinical isolates with different KPC variants (8A, 1B, 3B, 7B, 8B), no significant reduction in CZA MICs was observed for selected isolates with the restoration of functional wild type Ompk35 or Ompk36 (Table 2). CZA MIC differences between clinical isolates, transformants with wild type Ompk35, transformants with wild type Ompk36, and transformants with original blunt vector were no more than 2-fold.

Fig. 1
figure 1

Outer membrane protein profiles of selected representative clinical isolates and corresponding transformants. M: protein markers of 45, 35 and 25 kDa. The bands showed in ATCC13883 were Ompk35, Ompk36 and OmpkA

Full size image
Table 2 Effects of restoration of wild type Ompk35 and Ompk36 into clinical KPC-KP isolates
Full size table

Gene expression and copy number of bla KPC, and ompk35/36

There was no significant difference in relative gene expression and copy number of blaKPC, or ompk35/36 between the baseline isolates (A) and CZA-resistant isolates (B) (Fig. 2a, c, Fig. 3a, c, Fig. 4a, c). When we compared the baseline isolate and the CZA-resistant isolate recovered from the same patient, the relative gene expression of blaKPC in 1B was higher than 1A (Fig. 2b), while no significant difference was observed in isolates of other patients. The relative copy number of blaKPC in 1B was higher than 1A, the relative copy number of blaKPC in 3B and 7B were lower than 3A and 7A, and no significant difference in relative copy number was observed between 8A and 8B (Fig. 2d).

Fig. 2
figure 2

Relative gene expression (ab)and copy number (cd)of blaKPC in the baseline isolates (A) and CZA resistant isolates (B)

Full size image
Fig. 3
figure 3

Relative gene expression (ab)and copy number (cd)of Ompk35 in the baseline isolates (A) and CZA resistant isolates (B)

Full size image
Fig. 4
figure 4

Relative gene expression (ab)and copy number (cd)of Ompk36 in the baseline isolates (A) and CZA resistant isolates (B)

Full size image

No significant difference of gene expression and copy number of ompk35/36 were observed between 1A and 1B (Fig. 3b, d, Fig. 4b, d), while decreased ompk35 gene expression was found in CZA-resistant isolate with blaKPC-52 (8B) (Fig. 3b), and decreased ompk36 gene expression was found in other CZA-resistant isolates with blaKPC-33 (3B, and7B) (Fig. 4b).

The role of the AcrAB efflux pump

After the addition of PABN, CZA MICs of all selected isolates were not decreased by more than 2-fold (Table 1). This indicated that efflux is not a major mechanism for resistance to CZA.

Core genome phylogenetic analysis of isolated K. pneumoniae

Core genome phylogenetic analysis was performed to compare the 8 isolates from this study based on the results of WGS analysis and 157 of K. pneumonia strains filtered by MLST from NCBI (until July 2019). As shown in Fig. 5, all of the 8 isolates were located in a large branch (light purple, A-class) from the phylogenetic tree as a whole, which was almost from China except for 2 Canadian sources. Ten isolated strains can be divided into three groups. Groups 1 (isolate 3A, 3B) was the closest phylogenetic tree branch (L122, L222, L211, and L124) which were all isolated from Hangzhou China.

Fig. 5
figure 5

Maximum likelihood phylogeny based on SNPs in the core genomes of the K. pneumoniae ST11 strains isolated worldwide

Full size image

Discussion

In our report, we demonstrate a new mechanism of high-level CZA resistance in a KPC-producing K. pneumoniae strain in a lung transplant recipient, which is that high-level resistance to CZA is due to increased gene expression and copy number of the mutated blaKPC. Though increased blaKPC expression and copy number and/or Ompk defects were reported associated with increased CZA MICs [6, 21, 26], this result was often reported in isolates with wild type KPC, and the role of blaKPC expression and porins in isolates with mutated blaKPC is not clear. Our results have supplemented this evidence. In isolates with mutated blaKPC, the mutated blaKPC may play a major role in CZA resistance, and the increased gene expression and copy number of the mutated blaKPC could cause high-level CZA resistance, while the truncated Ompk35 may rarely contribute to the increased MIC of CZA.

Resistance to CZA has been reported in KPC-producing K. pneumoniae following treatment of CZA. Shields et al. first reported the evolution of CZA resistance during the treatment of K. pneumoniae infections in three patients from the United States in 2016 [3]. The treatment-emergent CZA resistance was subsequently described in Greece [27], Italy [9, 15, 16], Finland [10], Germany [12], and Spain [28] since then. And we recently reported four CZA-resistant KPC-KP recovered from lung transplant recipients after 13–22 days of CZA treatment in China [25].

KPC-31 [4] and KPC-33 [6] were the first two reported mechanisms associated with CZA resistance during treatment. Besides, KPC-35 [8], KPC-36 [15], KPC-41 [14], KPC-44 [10], KPC-48 [28], and KPC-57 [27] were also reported to be associated with acquired CZA resistance. We showed that CZA resistance in our 4 CZA-resistant isolates is due to mutations of blaKPC, and that two novel KPC variants (KPC-51, KPC-52) are also associated with CZA resistance [25]. The CZA MIC of the KPC-51-producing K. pneumoniae clinical isolate was the highest (2048 mg/L) in our study, while the CZA MIC for the KPC-51 E. coli DH5a transformant was only 8 mg/L. That indicated the variant KPC (KPC-51) is not the only mechanism of increased CZA MIC.

The role of mutated porins is not clear for CZA resistance. Modifications of Ompk35 and Ompk36, accompanied with various beta-lactamases, lead to carbapenem resistance, while do not influence CZA [29, 30]. However, several reports showed Ompk35/36 defects were associated with a high MIC of CZA. In the first reported CZA-resistant KPC-KP from a patient without CZA treatment [18], a nonfunctional Ompk35 (a premature stop codon at amino acid position 63) and a T333N mutation in Ompk36, were associated with impacted CZA susceptibility [22]. Castanheira et al. described a CZA-resistant K. pneumoniae displayed a premature stop codon in Ompk35 and decreased expression of Ompk36 [31]. Furthermore, Shields et al. reported mutations in Ompk36 were associated with CZA MICs [32]. Shen et al. showed that the restoration of functional Ompk35 resulted in a 2–4 fold decreased in the MICs of CZA for selected CZA-resistant isolates, indicating that the nonfunctional Ompk35 was related to CZA resistance [19]. Cui et al. reported the same ompk35 and ompk36 gene mutations were detected in reduced CZA susceptible strains and the CZA susceptible strains, which indicated that ompk35/36 mutations only partially contribute to the reduced susceptibility of CZA in the study [33]. Similarly, we observed that a truncated Ompk35 and a GD insertion at amino acid position 136–137 in Ompk36 in all our isolates, including 4 CZA-resistant isolates and 4 CZA-susceptible isolates.

The reports of K.pneumoniae harboring mutated KPC combined with porins defects were rare. A novel KPC variant (KPC-36) and porins defects were discovered in a CZA-resistant K.pneumoniae ST1519 (MIC = 16 mg/L) [15]. In another CZA-resistant K.pneumoniae (MIC = 64 mg/L) harboring KPC-53, porins defects could be detected [34].

We hypothesize that the different KPC variants combined with Ompk35/36 defects could lead to the different levels of CZA MIC, and the KPC-51 coupled with porins defects may lead to the highest MIC of CZA. However, after the restoration of functional Ompk35 or Ompk36, no significantly decreased CZA MICs were observed in CZA-resistant isolates. We believed that the mutated blaKPC was the most important mechanism in our isolates, and the mutations of Ompk35 or Ompk36 contribute no or rare to CZA resistance. The role of mutated porins for CZA should be further investigated.

The expression and copy number of blaKPC were often associated with reduced susceptibility to CZA. Overexpression of the blaKPC gene is a potential mechanism of CZA resistance in wild type blaKPC isolates. Nelson et al. reported that porins alteration combined with increased blaKPC-3 gene copy number and gene expression can cause CZA resistance [22]. And the relative blaKPC-2 copy numbers and relative expression of blaKPC-2 in the reduced susceptibility group were significantly higher than those in the susceptibility group [19, 23, 33]. For mutated blaKPC, the report of KPC variants combined with gene expression and copy number is rare. As we writing this article, one study [34] showed the increased blaKPC-53 gene dosage (two copies) coupled with porins alterations may lead to high-level CZA resistance (MIC = 64 mg/L). But there was only one strain with increased blaKPC-53 gene dosage was reported in the study, and the comparison between isolates with different KPC variants was not investigated.

Our results showed that the relative gene expression and copy number of blaKPC in isolate with the highest CZA MIC was higher than baseline isolate carrying wild type blaKPC-2, while this phenomenon did not appear in other CZA-resistant isolates. These results indicate that the mutated blaKPC was the dominant mechanism of CZA resistance in our isolates, and when combined with increased gene expression and copy number of blaKPC could lead to the higher level MIC of CZA.

This study is limited by its small patient population. CZA resistance was discovered before the widespread use of CZA in China. More research needs to be done, especially in data collected after the CZA treatment.

Conclusions

In summary, we found that mutated blaKPC is not the only mechanism related to CZA resistance, the increased gene expression and copy number of mutated blaKPC can cause high-level CZA resistance. With the use of CZA, more CZA resistant isolates have been reported worldwide, and more mechanisms of CZA resistance need to be explored. In consideration of the rapid acquisition of CZA resistance after therapy, our founding suggests that it is crucial to monitor the MIC of CZA in KPC-KP.

Methods

Isolates

Eight previously described isolates [25], including 4 baseline isolates recovered before CZA treatment and 4 corresponding CZA-resistant isolates recovered after CZA treatment, were analyzed in the present study. K. pneumoniae ATCC13883, K. pneumoniae ATCC700603, E.coli ATCC25922, and Salmonella enteric serotype Braenderup H9812 were used as reference isolates.

Antimicrobial susceptibility testing

Antimicrobial susceptibility testing performed using the VITEK-2 compact system (bioMerieux, Marcy-l’Etoile, France). Broth microdilution susceptibility testing of CZA was performed, and the result was interpreted according to the guidelines established by the Clinical and Laboratory Standards Institute (CLSI, M100, 2019). Avibactam was tested at a fixed concentration of 4 μg/ml in combination with increasing concentrations of ceftazidime. The reference strains E. coli ATCC25922, and K. pneumoniae ATCC700603 were used as controls.

Detection of genes encoding β-lactamases, and outer membrane proteins

PCR detection for the presence of beta-lactamase genes encoding carbapenemases (blaKPC, blaNDM-1, blaVIM, blaIMP, and blaOXA-48), ESBL associated genes (blaCTX-M, blaSHV, and blaTEM), and plasmid-borne AmpC beta-lactamases (blaACC, blaDHA, and blaCMY) were performed as described previously [35]. Outer membrane protein genes were amplified by PCR as described previously [36]. PCR amplicons were sequenced and compared with sequences available in the GenBank database using BLAST searches.

Quantitative real-time PCR (qRT-PCR) determinating gene expression and copy number of bla KPC and ompk35/36

The gene expression and copy number of blaKPC and ompk35/36 of 4 baseline isolates (A) and 4 CZA-resistant isolates (B) were examined as described previously [36,37,38], and the reference genes were listed in Table 3. Total RNA at mid-logarithmic growth phase bacterial cultures were obtained using RNeasy Mini Kit (Qiagen, Germany) and treated with RNase-Free DNase Set (Qiagen) in accordance with the manufacturer’s protocol. RT-PCR was performed using the QuantiTect SYBR Green RT-PCR Kit (Qiagen) on a QuantiStudio 12 K Flex system (Thermo Fisher Scientific). DNA was extracted by QIAamp DNA Mini Kit (Qiagen), and copy numbers were measured using the QuantiFast SYBR Green PCR Kit (Qiagen) on a QuantiStudio 12 K Flex system. K. pneumoniae house-keeping gene rpoB was used to normalize the gene expression and copy number of blaKPC and ompk35/36. Statistical analyses were performed using GraphPad Prism 9.

Table 3 Primers used in this study
Full size table

Cloning of ompK36 and ompK35 genes

The coding sequences of wild type ompk35 and ompk36 genes from reference isolate K. pneumoniae ATCC 13883 were amplified using primer pairs bluntOmpk35 (forward, 5′-AATGATGAAGCGCAATATTCT-3′; reverse, 5′- CGAAGGGGTGTACTGCAGATTA-3′) and bluntOmpk36 (forward, 5′- CATGAAAGTTAAAGTACTGTC-3′; reverse, 5′- TTATGCAGCTTGCAACTTAGAA-3′), respectively, and subsequently cloned into pEASY-Blunt vectors (Transgen Biotech Co., China). After nucleotide sequence verification, the kanamycin resistance gene of recombinant plasmids was replaced by the apramycin resistance gene using PCR. As a control, the kanamycin resistance gene in an empty vector was also replaced by the apramycin resistance gene. The recombinant plasmids were selected on Luria-Bertani (LB) agar containing apramycin at a concentration of 50 μg/ml.

Preparation of competent cells and electroporation

The competent cells of K. pneumoniae clinical isolates were prepared using 10% glycerol as previously described [39]. The mixture of 50ul electrocompetent cells and 5ul plasmid was transferred into a 2 mm electroporation cuvette and electroporated using MicroPuler System (Bio-Rad) at 2.5 kV. The cells were plated onto Luria-Bertani (LB) agar containing apramycin at 50 mg/L. The plates were incubated at 37 °C overnight, and the successful clone was identified using PCR and sequencing. The MICs of the recombinant strains were determined in the presence of IPTG at 100 μM [22].

Isolation and analysis of outer membrane components

Outer membrane proteins were isolated according to Carlone’s rapid procedure [40], and analyzed with SDS-PAGE.

Efflux pump inhibitor tests

MICs of CZA in combination with PABN (phenylalanine-arginine beta-naphthylamide) (25 mg/mL) [19, 41], a pump inhibitor, were determined. A fourfold decrease in MIC after the addition of PABN was considered significant.

Core genome phylogenetic analysis

WGS of all 8 isolates was carried out using the Illumina NovaSeq system in our previous study [25], and the assembled genome sequence has been deposited on NCBI with BioProject ‘PRJNA588110’. SNP analysis was performed using snippy software and the JM45 sequence was used for reference sequences. 8313 SNV sites were identified and the Modelfinder was used to find the best model. A phylogenetic tree was built by Iqtree [42, 43] with the best model (HKY + F + ASC + R4) and the number of bootstraps was set to 1000 times.

Availability of data and materials

Illumina sequence reads for the sequenced isolates in this study have been deposited in the NCBI sequence read archive are available in the sequence read archive under accessions ‘SRR10394536’(https://www.ncbi.nlm.nih.gov/search/all/?term=SRR10394536), ‘SRR10394605’(https://www.ncbi.nlm.nih.gov/search/all/?term=SRR10394605), ‘SRR10394910’(https://www.ncbi.nlm.nih.gov/search/all/?term=SRR10394910), ‘SRR10394933’(https://www.ncbi.nlm.nih.gov/search/all/?term=SRR10394933), ‘SRR10397948’(https://www.ncbi.nlm.nih.gov/search/all/?term=SRR10397948), ‘SRR10397950’(https://www.ncbi.nlm.nih.gov/search/all/?term=SRR10397950), ‘SRR10397951’(https://www.ncbi.nlm.nih.gov/search/all/?term=SRR10397951), ‘SRR10397953’(https://www.ncbi.nlm.nih.gov/search/all/?term=SRR10397953).

Abbreviations

cIAI:

complex intra-abdominal infections

CRE:

Carbapenem-resistant enterobacerales

CRKP:

Carbapenem-resistant Klebsiella pneumonia

CZA:

Ceftazidime/avibactam

HAP:

Hospital-acquired pneumonia

KPCs:

K. pneumoniae carbapenemases

KPC-Kp:

KPC-producing K. pneumoniae

LB:

Luria-Bertani

MIC:

Minimal inhibitory concentration

PABN:

Phenylalanine-arginine beta-naphthylamide

qRT-PCR:

Quantitative real-time PCR

ST11:

Sequence type 11

References

  1. Zhang Y, Wang Q, Yin Y, Chen H, Jin L, Gu B, et al. Epidemiology of carbapenem-resistant enterobacteriaceae infections: report from the China CRE network. Antimicrob Agents Chemother. 2018;62(2):e01882–17.

  2. van Duin D, Bonomo RA. Ceftazidime/avibactam and Ceftolozane/Tazobactam: second-generation beta-lactam/beta-lactamase inhibitor combinations. Clin Infect Dis. 2016;63(2):234–41. https://doi.org/10.1093/cid/ciw243.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for Carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2016;63(12):1615–8. https://doi.org/10.1093/cid/ciw636.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017;61(3):e02097–16.

  5. Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in Klebsiella pneumoniae carbapenemase-producing K pneumoniae: a case report and review of literature. Open Forum Infect Dis. 2017;4(3):ofx101.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Giddins MJ, Macesic N, Annavajhala MK, Stump S, Khan S, McConville TH, et al. Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates. Antimicrob Agents Chemother. 2018;62(3):e02101–17.

  7. Athans V, Neuner EA, Hassouna H, Richter SS, Keller G, Castanheira M, et al. Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant Klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient. Antimicrob Agents Chemother. 2019;63(1):e01551–18.

  8. Hemarajata P, Humphries RM. Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2. J Antimicrob Chemother. 2019;74(5):1241–3. https://doi.org/10.1093/jac/dkz026.

    CAS  Article  PubMed  Google Scholar 

  9. Gaibani P, Campoli C, Lewis RE, Volpe SL, Scaltriti E, Giannella M, et al. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. J Antimicrob Chemother. 2018;73(6):1525–9. https://doi.org/10.1093/jac/dky082.

    CAS  Article  PubMed  Google Scholar 

  10. Raisanen K, Koivula I, Ilmavirta H, Puranen S, Kallonen T, Lyytikainen O, et al. Emergence of ceftazidime-avibactam-resistant Klebsiella pneumoniae during treatment, Finland december 2018. Euro Surveill. 2019;24(19):1900256.

  11. Venditti C, Nisii C, D'Arezzo S, Vulcano A, Capone A, Antonini M, et al. Molecular and phenotypical characterization of two cases of antibiotic-driven ceftazidime-avibactam resistance in Bla KPC-3-harboring Klebsiella pneumoniae. Infect Drug Resist. 2019;12:1935–40. https://doi.org/10.2147/IDR.S207993.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. Gottig S, Frank D, Mungo E, Nolte A, Hogardt M, Besier S, et al. Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo. J Antimicrob Chemother. 2019;74(11):3211–6. https://doi.org/10.1093/jac/dkz330.

    CAS  Article  PubMed  Google Scholar 

  13. Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant enterobacteriaceae infections. Antimicrob Agents Chemother. 2018;62(5):e02497–17.

  14. Mueller L, Masseron A, Prod'Hom G, Galperine T, Greub G, Poirel L, et al. Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity. Antimicrob Agents Chemother. 2019;63(12):e01111–19.

  15. Gaibani P, Ambretti S, Campoli C, Viale P, Re MC. Genomic characterization of a Klebsiella pneumoniae ST1519 resistant to ceftazidime/avibactam carrying a novel KPC variant (KPC-36). Int J Antimicrob Agents. 2020;55(1):105816. https://doi.org/10.1016/j.ijantimicag.2019.09.020.

    CAS  Article  PubMed  Google Scholar 

  16. Antonelli A, Giani T, Di Pilato V, Riccobono E, Perriello G, Mencacci A, et al. KPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues. J Antimicrob Chemother. 2019;74(8):2464–6. https://doi.org/10.1093/jac/dkz156.

    CAS  Article  PubMed  Google Scholar 

  17. Both A, Buttner H, Huang J, Perbandt M, Belmar Campos C, Christner M, et al. Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate. J Antimicrob Chemother. 2017;72(9):2483–8. https://doi.org/10.1093/jac/dkx179.

    CAS  Article  PubMed  Google Scholar 

  18. Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, et al. First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother. 2015;59(10):6605–7. https://doi.org/10.1128/AAC.01165-15.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. Shen Z, Ding B, Ye M, Wang P, Bi Y, Wu S, et al. High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2017;72(7):1930–6. https://doi.org/10.1093/jac/dkx066.

    CAS  Article  PubMed  Google Scholar 

  20. Galani I, Antoniadou A, Karaiskos I, Kontopoulou K, Giamarellou H, Souli M. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam. Clin Microbiol Infect. 2019;25(6):763 e765–8.

    Article  Google Scholar 

  21. Humphries RM, Hemarajata P. Resistance to ceftazidime-avibactam in Klebsiella pneumoniae due to porin mutations and the increased expression of KPC-3. Antimicrob Agents Chemother. 2017;61(6):e00537–17.

  22. Nelson K, Hemarajata P, Sun D, Rubio-Aparicio D, Tsivkovski R, Yang S, et al. Resistance to ceftazidime-avibactam is due to transposition of KPC in a porin-deficient strain of Klebsiella pneumoniae with increased efflux activity. Antimicrob Agents Chemother. 2017;61(10):e00989–17.

  23. Zhang P, Shi Q, Hu H, Hong B, Wu X, Du X, et al. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China. Clin Microbiol Infect. 2020;26(1):124 e121–4.

    Article  Google Scholar 

  24. Chen W, Sun L, Guo L, Cao B, Liu Y, Zhao L, et al. Clinical outcomes of ceftazidime-avibactam in lung transplant recipients with infections caused by extensively drug-resistant gram-negative bacilli. Ann Transl Med. 2020;8(3):39. https://doi.org/10.21037/atm.2019.10.40.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  25. Sun L, Chen W, Li H, Li L, Zou X, Zhao J, et al. Phenotypic and genotypic analysis of KPC-51 and KPC-52, two novel KPC-2 variants conferring resistance to ceftazidime/avibactam in the KPC-producing Klebsiella pneumoniae ST11 clone background. J Antimicrob Chemother. 2020;75(10):3072–4. https://doi.org/10.1093/jac/dkaa241.

    CAS  Article  PubMed  Google Scholar 

  26. Coppi M, Di Pilato V, Monaco F, Giani T, Conaldi PG, Rossolini GM. Ceftazidime-avibactam resistance associated with increased bla KPC-3 gene copy number mediated by pKpQIL Plasmid derivatives in sequence type 258 Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020;64(4):e01816–19.

  27. Galani I, Karaiskos I, Angelidis E, Papoutsaki V, Galani L, Souli M, et al. Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment. Eur J Clin Microbiol Infect Dis. 2021;40(1):219–24. https://doi.org/10.1007/s10096-020-04000-9.

    CAS  Article  PubMed  Google Scholar 

  28. Cano A, Guzman-Puche J, Garcia-Gutierrez M, Caston JJ, Gracia-Ahufinger I, Perez-Nadales E, et al. Use of carbapenems in the combined treatment of emerging ceftazidime/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: report of a case and review of the literature. J Glob Antimicrob Resist. 2020;22:9–12. https://doi.org/10.1016/j.jgar.2019.11.007.

    Article  PubMed  Google Scholar 

  29. Pulzova L, Navratilova L, Comor L. Alterations in outer membrane permeability favor drug-resistant phenotype of Klebsiella pneumoniae. Microb Drug Resist. 2017;23(4):413–20. https://doi.org/10.1089/mdr.2016.0017.

    CAS  Article  PubMed  Google Scholar 

  30. Wong JLC, Romano M, Kerry LE, Kwong HS, Low WW, Brett SJ, et al. OmpK36-mediated Carbapenem resistance attenuates ST258 Klebsiella pneumoniae in vivo. Nat Commun. 2019;10(1):3957. https://doi.org/10.1038/s41467-019-11756-y.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  31. Castanheira M, Mendes RE, Sader HS. Low frequency of ceftazidime-avibactam resistance among enterobacteriaceae isolates carrying blaKPC Collected in U.S. hospitals from 2012 to 2015. Antimicrob Agents Chemother. 2017;61(3):e02369–16.

  32. Shields RK, Clancy CJ, Hao B, Chen L, Press EG, Iovine NM, et al. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum beta-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae. Antimicrob Agents Chemother. 2015;59(9):5793–7. https://doi.org/10.1128/AAC.00548-15.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  33. Cui X, Shan B, Zhang X, Qu F, Jia W, Huang B, et al. Reduced ceftazidime-avibactam susceptibility in KPC-producing Klebsiella pneumoniae from patients without ceftazidime-avibactam use history - a multicenter study in China. Front Microbiol. 2020;11:1365. https://doi.org/10.3389/fmicb.2020.01365.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Di Pilato V, Aiezza N, Viaggi V, Antonelli A, Principe L, Giani T, et al. KPC-53, a KPC-3 variant of clinical origin associated with reduced susceptibility to ceftazidime-avibactam. Antimicrob Agents Chemother. 2020:65(1):e01429–20.

  35. Li B, Yi Y, Wang Q, Woo PC, Tan L, Jing H, et al. Analysis of drug resistance determinants in Klebsiella pneumoniae isolates from a tertiary-care hospital in Beijing, China. PLoS One. 2012;7(7):e42280. https://doi.org/10.1371/journal.pone.0042280.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  36. Doumith M, Ellington MJ, Livermore DM, Woodford N. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother. 2009;63(4):659–67. https://doi.org/10.1093/jac/dkp029.

    CAS  Article  PubMed  Google Scholar 

  37. Ruzin A, Visalli MA, Keeney D, Bradford PA. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2005;49(3):1017–22. https://doi.org/10.1128/AAC.49.3.1017-1022.2005.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  38. Kitchel B, Rasheed JK, Endimiani A, Hujer AM, Anderson KF, Bonomo RA, et al. Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2010;54(10):4201–7. https://doi.org/10.1128/AAC.00008-10.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  39. Wang Y, Wang S, Chen W, Song L, Zhang Y, Shen Z, et al. CRISPR-Cas9 and CRISPR-assisted cytidine deaminase enable precise and efficient genome editing in Klebsiella pneumoniae. Appl Environ Microbiol. 2018;84(23):e01834–18.

  40. Carlone GM, Thomas ML, Rumschlag HS, Sottnek FO. Rapid microprocedure for isolating detergent-insoluble outer membrane proteins from Haemophilus species. J Clin Microbiol. 1986;24(3):330–2. https://doi.org/10.1128/jcm.24.3.330-332.1986.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  41. Li XZ, Plesiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in gram-negative bacteria. Clin Microbiol Rev. 2015;28(2):337–418. https://doi.org/10.1128/CMR.00117-14.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Nguyen LT, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol Biol Evol. 2015;32(1):268–74. https://doi.org/10.1093/molbev/msu300.

    CAS  Article  PubMed  Google Scholar 

  43. Hoang DT, Chernomor O, von Haeseler A, Minh BQ, Vinh LS. UFBoot2: improving the ultrafast bootstrap approximation. Mol Biol Evol. 2018;35(2):518–22. https://doi.org/10.1093/molbev/msx281.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Pro. Hui Wang, Jiankang Zhao, Xiaohui Zou, Shuai Liu, Xiaoxuan Feng, and Longyang Jin for their assistance.

Funding

This study was supported by the National Key R&D Program of China (2017YFC1309301, 2017YFC1309300), the CAMS Innovation Fund for Medical Sciences (CIFMS 2018-I2M-1–003), and the National Science Grant for Distinguished Young Scholars (81425001/H0104) (Bin Cao). The funding bodies played no role in the design of the study, collection, analysis, and interpretation of data, and in writing the manuscript.

Author information

Authors and Affiliations

  1. National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Capital Medical University, Beijing, China

    Lingxiao Sun & Bin Cao

  2. Laboratory of Clinical Microbiology and Infectious Diseases, Department of Pulmonary and Critical Care Medicine, Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China

    Lingxiao Sun, Haibo Li, Yingmei Liu & Bin Cao

  3. National Clinical Research Center of Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Science, Beijing, China

    Lingxiao Sun, Haibo Li, Yingmei Liu & Bin Cao

  4. Department of Clinical Laboratory, Peking University People’s Hospital, Beijing, China

    Qi Wang

  5. Tsinghua University-Peking University Joint Center for Life Sciences, Beijing, China

    Bin Cao

Authors
  1. Lingxiao Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haibo Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yingmei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bin Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study concept and design: LxS, HbL, YmL, and BC. Acquisition of data: LxS, HbL, and QW. Statistical analysis of data: LxS. Drafting of the manuscript: LxS. Critical revision of the manuscript for important intellectual content: YmL and BC. Study supervision: BC. All authors read and approved the study.

Corresponding authors

Correspondence to Yingmei Liu or Bin Cao.

Ethics declarations

Ethics approval and consent to participate

Permission for using the raw data and the isolates for research purposes was approved by the Ethics Committee of the China-Japan Friendship Hospital (2019–164-K113). Because of the retrospective nature of this study, informed consent is not needed. The data used in this study was anonymised before its use.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sun, L., Li, H., Wang, Q. et al. Increased gene expression and copy number of mutated blaKPC lead to high-level ceftazidime/avibactam resistance in Klebsiella pneumoniae. BMC Microbiol 21, 230 (2021). https://doi.org/10.1186/s12866-021-02293-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12866-021-02293-0

Keywords

  • Ceftazidime/avibactam resistance
  • Minimal inhibitory concentration
  • Mutated bla KPC
  • Outer membrane protein
  • Electroporation

BMC Microbiology

ISSN: 1471-2180

Contact us